Biomind Labs Files Disclosure and Appoints New Board Member

Biomind Labs Inc., a biotech firm listed on CBOE, OTC PINK, and FRA, has filed several amended disclosure documents on SEDAR+. These include management's discussions and analyses and financial statements for various periods ending in 2025. The amendments were made following a request by the Ontario Securities Commission to enhance clarity about the company’s operations and governance.

In addition to these filings, Biomind Labs announced the appointment of Scott Ackerman as an independent director and audit committee member. Ackerman is the CEO of Emprise Capital Corp., bringing years of experience in restructuring services for public companies.

Biomind is under a cease trade order for not filing 2024 audited financials. The company has since submitted necessary documents, which can be accessed on SEDAR+.